GlassScriptPhysician profile
Sarah Whitehead
NPI 1013352954
$3,451.11
in general payments reported to CMS, 2019-2025
36 companies · $770 in 2025
The $770 reported for 2025 was more than what 88% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $490 · 2020: $264 · 2021: $347 · 2022: $651 · 2023: $615 · 2024: $313 · 2025: $770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,228 · Travel and Lodging: $370 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,228.20 |
| Travel and Lodging | $370.21 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $615.46 | 2022-2025 | |
| Abbvie INC. | $274.47 | 2019-2023 | Lo Loestrin Fe |
| Pfizer INC. | $241.46 | 2019-2023 | |
| Astellas Pharma US INC | $232.21 | 2019-2024 | Veozah |
| Mayne Pharma Commercial LLC | $174.77 | 2021-2023 | |
| Sumitomo Pharma America, INC. | $164.86 | 2023-2024 | Myfembree |
| Organon LLC | $160.86 | 2021-2025 | Nexplanon |
| Integra Lifesciences Corporation | $151.63 | 2025 | Tenoglide |
| Amgen INC. | $149.67 | 2019-2021 | |
| Myovant Sciences INC. | $135.10 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $117.39 | 2019-2025 | |
| Becton, Dickinson and Company | $106.03 | 2019-2022 | |
| Scynexis, INC. | $101.36 | 2021-2022 | |
| Therapeuticsmd, INC. | $99.91 | 2019-2022 | |
| Evofem Biosciences, INC. | $70.26 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $68.62 | 2021-2023 | Slynd |
| Hologic Sales and Service, LLC | $56.26 | 2024-2025 | Aptima, Myosure Tissue Removal Device, Novasure |
| Coopersurgical, INC. | $56.20 | 2020-2024 | Paragard T 380a, Paragard T 380a |
| Sage Therapeutics, LLC | $52.79 | 2020-2024 | |
| Lilly USA, LLC | $48.89 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Minerva Surgical, INC | $48.61 | 2020-2024 | |
| Novo Nordisk INC | $46.82 | 2025 | |
| Merck Sharp & Dohme LLC | $43.08 | 2019-2023 | Gardasil 9 |
| Amag Pharmaceuticals, INC. | $26.50 | 2019 | |
| Lupin INC. | $24.34 | 2020 | |
| Mylan Pharmaceuticals INC. | $23.16 | 2020-2022 | |
| Applied Medical Resources Corporation | $19.22 | 2023 | |
| Agile Therapeutics, INC. | $18.53 | 2021 | |
| Vertical Pharmaceuticals, LLC | $17.63 | 2019 | |
| Millicent US INC | $17.59 | 2023 | Intrarosa |
| Convatec INC. | $17.07 | 2022 | |
| Shield Therapeutics INC | $16.99 | 2023 | Accrufer |
| Daiichi Sankyo INC. | $16.08 | 2019 | |
| Urovant Sciences INC | $15.69 | 2022 | |
| Glaxosmithkline, LLC. | $11.02 | 2020 | |
| Acessa Health INC. | $10.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Whitehead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.